ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support
RNS Number : 7652T MaxCyte, Inc. 22 March 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options and PDMR Dealing Gaithersburg, Maryland - 22 March 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 1392T MaxCyte, Inc. 16 March 2023 MaxCyte announces filing of Form 10-K for the full year period ended December 31, 2022 ROCKVILLE, MD , March 16, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 1351T MaxCyte, Inc. 16 March 2023 MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results 31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue ROCKVILLE, MD , March 16, 2023 -
31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the discovery, development and manufacturing of next-generation, cell-based medicines ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc.
RNS Number : 3036S MaxCyte, Inc. 08 March 2023 MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology MaxCyte's Scientific Advisory Board will provide guidance to shape the technical direction of the company's
RNS Number : 0738S MaxCyte, Inc. 07 March 2023 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance · Full year 2022 total revenue expected to be approximately $44.3 million , representing growth of 31% over full year
Full year 2022 total revenue expected to be approximately $44.3 million, representing growth of 31% over full year 2021 Fourth quarter 2022 total revenue expected to be approximately $12.4 million, representing growth of 22% over fourth quarter 2021 Installed base at year end 2022 of greater than
RNS Number : 0685P MaxCyte, Inc. 06 February 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options, PDMR dealing and Total Voting Rights ROCKVILLE, MD , February 6, 2023 - MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on
